Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

被引：33

作者：

Lima, Caio M. Rocha ^{[1
,2
]}

Bayraktar, Soley ^{[1
,2
]}

Flores, Aurea M. ^{[1
,2
]}

MacIntyre, Jessica ^{[1
,2
]}

Montero, Alberto ^{[1
,2
]}

Baranda, Joaquina C. ^{[3
]}

Wallmark, John ^{[4
]}

Portera, Chia ^{[5
]}

Raja, Rajiv ^{[5
]}

Stern, Howard ^{[5
]}

Royer-Joo, Stephanie ^{[5
]}

Amler, Lukas C. ^{[5
]}

机构：

[1] Univ Miami, Div Hematol Oncol, Miami, FL 33136 USA

[2] Univ Miami Hosp & Clin, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Univ Kansas, Med Ctr, Dept Med Oncol, Kansas City, KS 66103 USA

[4] Associates Oncol Hematol PC, Rockville, MD USA

[5] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER INVESTIGATION | 2012年 / 30卷 / 10期

关键词：

Drozitumab; Metastatic colorectal cancer; Apo2; ligand; Apoptosis; Toxicity; Efficacy; CLINICAL-TRIALS; CHEMOTHERAPY;

D O I：

10.3109/07357907.2012.732163

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.

引用

页码：727 / 731

页数：5

共 50 条

[1] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
Lima, C. S. Rocha
Baranda, J. C.
Wallmark, J.
Choi, Y.
Royer-Joo, S.
Portera, C. C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[2] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
Belhadef, S.
Arab, A.
Belmadi, M.
Beninal, M.
Bacha, N.
Abdallah, R.
Mechta, K.
Dahmane, A.
Mahfouf, H.
Oukkal, M.
Bouzid, K.
Faraqun, S.
Bentabak, K.
Younes, S. Ait
ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
[3] A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients
Van Cutsem, E.
Prenen, H.
D'Haens, G.
Bennouna, J.
Carrato, A.
Ducreux, M.
Bouche, O.
Sobrero, A.
Latini, L.
Staines, H.
Oum'Hamed, Z.
Dressler, H.
Studeny, M.
Capdevila, J.
ANNALS OF ONCOLOGY, 2015, 26 (10) : 2085 - 2091
[4] Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer
Bayoglu, Ibrahim Vedat
Yildiz, Ibrahim
Varol, Umut
Cokmert, Suna
Kucukzeybek, Yuksel
Alacacioglu, Ahmet
Demir, Lutfiye
Dirican, Ahmet
Akyol, Murat
Yildiz, Yasar
Tarhan, Mustafa Oktay
JOURNAL OF BUON, 2015, 20 (02): : 460 - 467
[5] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Yamazaki, K.
Nagase, M.
Tamagawa, H.
Ueda, S.
Tamura, T.
Murata, K.
Nakajima, T. Eguchi
Baba, E.
Tsuda, M.
Moriwaki, T.
Esaki, T.
Tsuji, Y.
Muro, K.
Taira, K.
Denda, T.
Funai, S.
Shinozaki, K.
Yamashita, H.
Sugimoto, N.
Okuno, T.
Nishina, T.
Umeki, M.
Kurimoto, T.
Takayama, T.
Tsuji, A.
Yoshida, M.
Hosokawa, A.
Shibata, Y.
Suyama, K.
Okabe, M.
Suzuki, K.
Seki, N.
Kawakami, K.
Sato, M.
Fujikawa, K.
Hirashima, T.
Shimura, T.
Taku, K.
Otsuji, T.
Tamura, F.
Shinozaki, E.
Nakashima, K.
Hara, H.
Tsushima, T.
Ando, M.
Morita, S.
Boku, N.
Hyodo, I.
ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
[6] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
van Hazel, Guy A.
Heinemann, Volker
Sharma, Navesh K.
Findlay, Michael P. N.
Ricke, Jens
Peeters, Marc
Perez, David
Robinson, Bridget A.
Strickland, Andrew H.
Ferguson, Tom
Rodriguez, Javier
Kroening, Hendrik
Wolf, Ido
Ganju, Vinod
Walpole, Euan
Boucher, Eveline
Tichler, Thomas
Shacham-Shmueli, Einat
Powell, Alex
Eliadis, Paul
Isaacs, Richard
Price, David
Moeslein, Fred
Taieb, Julien
Bower, Geoff
Gebski, Val
Van Buskirk, Mark
Cade, David N.
Thurston, Kenneth
Gibbs, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1723 - +
[7] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
Nishina, Tomohiro
Takano, Yoshinao
Denda, Tadamichi
Yasui, Hisateru
Takeda, Koji
Ura, Takashi
Esaki, Taito
Okuyama, Yusuke
Kondo, Ken
Takahashi, Yasuo
Sugiyama, Yasuyuki
Muro, Kei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
[8] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
Graham, C. N.
Hechmati, G.
Hjelmgren, J.
De Liege, F.
Lanier, J.
Knoof, A.
Knox, H.
Barber, B.
de Pouvourville, G.
VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
[9] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
Graham, Christopher N.
Hechmati, Guy
Hjelmgren, Jonas
de Liege, Frederique
Lanier, Julie
Knox, Hediyyih
Barber, Beth
EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
[10] Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)
Keisuke Miwa
Eiji Oki
Yasunori Emi
Hiroshi Saeki
Tetsuya Kusumoto
Yoshito Akagi
Yutaka Ogata
Hironori Samura
Shoji Tokunaga
Hiroshi Ishikawa
Takaho Tanaka
Susumu Sueyoshi
Hidefumi Higashi
Hiroyuki Matsuda
Tetsuo Touyama
Yoshihiko Maehara
International Journal of Clinical Oncology, 2016, 21 : 110 - 117

← 1 2 3 4 5 →